Profile data is unavailable for this security.
About the company
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. It has developed monoclonal antibodies to help treat different diseases. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes more than 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines include medicines for immune-mediated conditions. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases.
- Revenue in USD (TTM)37.95bn
- Net income in USD6.17bn
- Incorporated1999
- Employees70.21k
- LocationGSK plc980 Great West RoadBRENTFORD TW8 9GSUnited KingdomGBR
- Phone+44 208 047 5000
- Fax+44 208 047 7807
- Websitehttps://www.gsk.com/
Mergers & acquisitions
| Acquired company | GSK:LSE since announced | Transaction value |
|---|---|---|
| Aiolos Bio Inc | 6.71% | 1.40bn |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zoetis Inc | 8.54bn | 2.34bn | 70.08bn | 14.10k | 30.25 | 14.07 | 24.75 | 8.20 | 5.07 | 5.07 | 18.48 | 10.90 | 0.585 | 1.03 | 6.78 | 605,957.40 | 16.02 | 14.47 | 19.37 | 17.18 | 70.47 | 69.80 | 27.39 | 25.77 | 2.00 | 17.15 | 0.5682 | 26.89 | 5.74 | 7.96 | 10.88 | 11.13 | 16.71 | 24.37 |
| Gilead Sciences, Inc. | 27.12bn | 5.66bn | 81.39bn | 18.00k | 14.49 | 3.56 | 9.80 | 3.00 | 4.50 | 4.50 | 21.56 | 18.33 | 0.4328 | 3.95 | 5.75 | 1,506,445.00 | 8.96 | 6.74 | 10.91 | 8.12 | 76.04 | 78.64 | 20.69 | 16.95 | 1.27 | 8.78 | 0.5234 | 81.22 | -0.6048 | 4.15 | 23.37 | 0.7436 | -8.74 | 5.64 |
| GSK plc (ADR) | 37.95bn | 6.17bn | 85.08bn | 70.21k | 13.59 | 4.97 | 8.34 | 2.24 | 3.01 | 3.01 | 18.50 | 8.23 | 0.5091 | 1.57 | 4.20 | 540,496.90 | 8.91 | 6.74 | 13.91 | 10.71 | 72.42 | 70.29 | 17.50 | 16.93 | 0.624 | 10.99 | 0.5848 | 79.55 | 3.42 | -0.322 | 15.79 | 7.10 | 5.47 | -- |
| Bristol-Myers Squibb Co | 45.01bn | 8.03bn | 90.60bn | 34.10k | 11.59 | 3.07 | 5.09 | 2.01 | 3.86 | 3.86 | 21.66 | 14.56 | 0.4689 | 4.24 | 5.01 | 1,319,824.00 | 8.38 | 3.05 | 10.89 | 3.76 | 76.44 | 76.13 | 17.86 | 7.69 | 1.31 | 12.39 | 0.5743 | 133.63 | -2.50 | 14.81 | 26.84 | 10.03 | 4.92 | 7.34 |
| Regeneron Pharmaceuticals Inc | 13.12bn | 3.95bn | 97.76bn | 13.45k | 25.62 | 3.75 | 22.35 | 7.45 | 34.76 | 34.76 | 115.32 | 237.41 | 0.4211 | 0.7289 | 2.39 | 975,256.50 | 12.69 | 20.18 | 14.19 | 23.22 | 86.16 | 86.63 | 30.14 | 38.11 | 4.94 | -- | 0.0943 | -- | 7.76 | 14.34 | -8.87 | 10.72 | 19.32 | -- |
| Vertex Pharmaceuticals Incorporated | 9.87bn | 3.62bn | 102.79bn | 5.40k | 28.63 | 5.83 | 27.04 | 10.42 | 13.89 | 13.89 | 37.88 | 68.22 | 0.4828 | 2.10 | 6.57 | 1,827,630.00 | 17.71 | 19.92 | 20.93 | 23.64 | 87.21 | 87.67 | 36.68 | 35.85 | 3.78 | -- | 0.021 | 0.00 | 10.51 | 26.49 | 8.96 | 46.50 | 22.02 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Dodge & Coxas of 31 Dec 2023 | 69.03m | 3.33% |
| JTC Plc /Private Banking/as of 31 Mar 2024 | 21.14m | 1.02% |
| Fisher Asset Management LLCas of 31 Dec 2023 | 15.04m | 0.73% |
| PRIMECAP Management Co.as of 31 Dec 2023 | 12.09m | 0.58% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 10.47m | 0.51% |
| Holocene Advisors, LPas of 31 Dec 2023 | 8.22m | 0.40% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 7.05m | 0.34% |
| T. Rowe Price International Ltd.as of 31 Dec 2023 | 6.84m | 0.33% |
| Strategic Advisers LLCas of 31 Dec 2023 | 6.80m | 0.33% |
| RBC Capital Markets LLC (Investment Management)as of 31 Dec 2023 | 6.63m | 0.32% |
